Gossamer Bio, Inc. 8K

Gossamer Bio reported Q2 2026 results, advanced its planned seralutinib NDA after a Pre‑NDA FDA meeting, reacquired global rights to seralutinib from Chiesi, and significantly reduced its debt through a convertible note exchange approved by stockholders alongside authorization for a reverse stock split.

On August 13, 2026, Gossamer Bio, Inc. reported its second quarter 2026 financial results and business update, highlighting that its NDA submission for seralutinib in pulmonary arterial hypertension remains on track for September 2026 following a Pre‑NDA Type B FDA meeting, under which the FDA characterized efficacy issues as review rather than filing matters. The company also terminated its Collaboration and License Agreement with Chiesi and reacquired worldwide development and commercial rights to seralutinib, receiving a one‑time $5 million payment and agreeing to provide Chiesi with capped royalties and milestone payments, thereby consolidating global control and the majority of the asset’s economics. At a July 14, 2026 special meeting, stockholders approved proposals supporting the previously completed exchange of approximately $181.1 million (90.5%) of its 5.00% Convertible Senior Notes due 2027 into new 7.50% Convertible Senior Secured First Lien Notes due 2030 plus equity and warrants, materially reducing total debt and authorizing the board to effect a reverse stock split. Financially, Gossamer reported Q2 2026 revenue of $9.2 million primarily from its Chiesi collaboration, R&D expenses of $26.4 million, G&A expenses of $8.9 million, and net income of $16.9 million, with $57.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which it expects to fund operations into the first quarter of 2027.

Filing Facts

CIK

1728117

Ticker

-

Form

8K

Source Type

sec

Accession

0001728117-26-000073

Alert Tier

7